Kirsten Bibbins-Domingo, PhD, MD; Alicia Fernandez, MD
Acknowledgments: The authors thank the organizers and participants of the special symposium on the implications of BiDil at the 2005 Society of General Internal Medicine Annual Meeting, New Orleans, Louisiana, 11–14 May 2005, including Drs. Giselle Corbie-Smith, Carol Horowitz, Valerie Stone, Christopher Phillips, and Jack Geiger.
Grant Support: Dr. Bibbins-Domingo is supported by grants from the Robert Wood Johnson Foundation (Amos Medical Faculty Development award) and the National Heart, Lung, and Blood Institute (contract no. N01-HC-95095), and Dr. Fernandez is supported by a K23 award from the National Center for Research Resources of the National Institutes of Health (K23 RR01832401).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Kirsten Bibbins-Domingo, PhD, MD, Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, Box 1364, San Francisco, CA 94143-1364; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Bibbins-Domingo and Fernandez: Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, Box 1364, San Francisco, CA 94143-1364.
Bibbins-Domingo K, Fernandez A. BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval. Ann Intern Med. 2007;146:52–56. doi: https://doi.org/10.7326/0003-4819-146-1-200701020-00009
Download citation file:
Published: Ann Intern Med. 2007;146(1):52-56.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use